New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
Retrieved on:
Tuesday, September 6, 2022
Carpal tunnel syndrome, COVID-19, Fatigue, ENEA, Pain, Securities Act of 1933, Research, Liver, SAN, Medication, Evolve, Drug Quality and Security Act, Injection, Carcinoid syndrome, Hormone, GLOBE, Metabolism, Degenerative disease, Patient, Time, Glucose, Adenoma, SEC, Universiade, Arthritis, FDA, Growth hormone, Drug discovery, Intellectual property, Sleep apnea, Annual report, Arthralgia, Congenital hyperinsulinism, SRL, SST2, Securities Exchange Act of 1934, Form 10-K, Lipid metabolism, Pituitary adenoma, Sequoyah, Vocal cords, GH, Marketing, Needle, Congenital adrenal hyperplasia, Doctor of Philosophy, Advance, Wilms' tumor, Heart, ACTH, Human, Medical school, Therapy, Clinical trial, OLE, Pharmaceutical industry, Endocrinology, Acromegaly, MD
SAN DIEGO, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX) today announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, presented new data from the planned two-year interim analysis of the ACROBAT Advance open label extension (OLE) study at the 35th Brazilian Congress of Endocrinology and Metabolism (CBEM).
Key Points:
- This preliminary data, combined with the preference participants had for oral paltusotine over the injected standard-of-care, speaks to the potential paltusotine may have as a long-term therapy for acromegaly.
- Dr. Gadelha will present an additional poster of the Advance OLE data at the European Neuroendocrine Association (ENEA) meeting.
- That presentation, titled Long-Term Treatment with Oral Paltusotine for Acromegaly: Results from the ACROBAT Advance study will be made on September 9th.
- In Phase 2 trials, paltusotine maintained IGF-1 levels in acromegaly patients who switched from injectable depot medications to once-daily paltusotine.